UK based company GSK has been planning to roll out a billion doses of its potential vaccine for the coronavirus being developed in collaboration with the vaccine major Sanofi in the second half of 2021.
The GSK is touted to use its well established ‘adjuvant’ platform with Sanofi’s protein-based antigen technology. Rolling out a vaccine in 15-18 months is usually considered to be a miracle. However, prior research with regards to SARS and MERS have enabled faster development of a possible drug in the case of COVID-19. After clearing clinical trials and regulatory approvals, the UK based company is confident of supplying a billion doses in the year 2021. Furthermore, the company in an interaction with the media on Wednesday stated that it was too early to give out many details about the vaccine, however, adding that the global access to a possible COVID-19 vaccine is a priority.
In the past, homegrown pharma major Cipla Ltd had announced that it has signed a non-exclusive licensing agreement with Gilead Sciences Inc. for manufacturing and distribution of investigational drug Remdesivir, a potential therapy for the coronavirus. On the other hand, Indian Pharmaceuticals have tested a leprosy drug on COVID-19 patients in Chandigarh. This drug contains an immunomodulatory element which as per the Indian Council of Medical Research can help treat the mortality rate in COVID-19 patients.
Tech Mahindra has been known to investigate Artificial Intelligence (AI) in order to study potential therapeutic drugs for COVID-19. CP Gurnani, MD and CEO of Tech Mahindra in a statement said by leveraging cutting edge and futuristic technology, a potential treatment for COVID-19 can be formulated. Nikhil Malhotra, Global Head of maker’s lab, on the other hand, stated, that "the use of AI further helped the team to evaluate multiple scenarios with different parameters while finding how molecules dock with the main protease."
Share
Tweet
